US FDA Lifts Partial Clinical Hold on Karyopharm’s Selinexor Clinical Trials

When there is so much that is negative in the news, it is great to be able to report today that myeloma clinical trials with selinexor (KPT-330) can again move forward.

Prioritizing the search for new drugs to achieve a permanent remission

In the two weeks since we lost one of our most beloved patients, our inability to cure myeloma has been staring us in the face.  It was absolutely wonderful that Mike Katz lived 25 years after his initial diagnosis. But we need decisively better drugs to achieve our goal of permanent remission. Until we cure myeloma, the extensions of life we achieve are only as good as the next new drug emerging from around that next corner.